New Drug Approvals In 2003 Could Include Four HIV Agents
Executive Summary
FDA's new molecular entity approvals for 2003 could feature as many as four novel HIV agents
You may also be interested in...
Genentech Rx For Global Pricing: Refuse To Sell Unless Price Is “Reasonable”
Pharmaceutical companies should not market products in countries that do not allow "reasonable" prices for drugs, Genentech CEO Arthur Levinson declared during a March 12 investor conference
Genentech Rx For Global Pricing: Refuse To Sell Unless Price Is “Reasonable”
Pharmaceutical companies should not market products in countries that do not allow "reasonable" prices for drugs, Genentech CEO Arthur Levinson declared during a March 12 investor conference
FDA Clears 21 NMEs In 2003; Average Approval Time Is 16.6 Months
FDA finished 2003 with slightly more new molecular entity approvals at a slightly faster pace than its 2002 performance